ArticleLeukemia2017
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.Blood · 2017Trial
- Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias.Journal of cancer research and clinical oncology · 2026Article
- Comparative efficacy and safety of JAK inhibitor-based strategies in JAK inhibitor-naïve myelofibrosis: A systematic review and network meta-analysis.Therapeutic advances in hematology · 2026Article
- Plasma cfDNA and peripheral blood gDNA provide complementary information for molecular monitoring in myeloproliferative neoplasms.Frontiers in oncology · 2026Article
- [Efficacy of ruxolitinib and prognostic factors in patients with myelofibrosis stratified by age].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling.Nature communications · 2025Article
- The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells.Frontiers in immunology · 2024Article
- Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinibFrontiers in oncology · 2023Article
- Article
- Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2022Review
- [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?Cancers · 2021Review
- MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.International journal of hematology · 2021Article
- A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34Oncology letters · 2021Article
- Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro.Blood advances · 2020Article
- Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.JCO oncology practice · 2020Review
- Guidance on changing therapy choice in myelofibrosis.Blood advances · 2020Article
- Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.International journal of hematology · 2020Review
- Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice.International journal of hematology · 2019Article
Corrections and comments
- Erratum for
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.